Predictive value of C-X-C motif chemokine receptor 4-directed molecular imaging in patients with advanced adrenocortical carcinoma.

IF 7.6 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING European Journal of Nuclear Medicine and Molecular Imaging Pub Date : 2024-10-01 Epub Date: 2024-06-19 DOI:10.1007/s00259-024-06800-z
Wiebke Schloetelburg, Philipp E Hartrampf, Aleksander Kosmala, Sebastian E Serfling, Niklas Dreher, Andreas Schirbel, Martin Fassnacht, Andreas K Buck, Rudolf A Werner, Stefanie Hahner
{"title":"Predictive value of C-X-C motif chemokine receptor 4-directed molecular imaging in patients with advanced adrenocortical carcinoma.","authors":"Wiebke Schloetelburg, Philipp E Hartrampf, Aleksander Kosmala, Sebastian E Serfling, Niklas Dreher, Andreas Schirbel, Martin Fassnacht, Andreas K Buck, Rudolf A Werner, Stefanie Hahner","doi":"10.1007/s00259-024-06800-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In patients affected with adrenocortical carcinoma (ACC), C-X-C motif chemokine receptor 4 (CXCR4) is highly expressed in sites of disease in an ex-vivo setting. We aimed to determine the predictive value of CXCR4-targeting [<sup>68</sup>Ga]Ga-PentixaFor PET/CT for outcome when compared to clinical parameters.</p><p><strong>Methods: </strong>We identified 41 metastasized ACC patients imaged with [<sup>68</sup>Ga]Ga-PentixaFor PET/CT. Scans were assessed visually and on a quantitative level by manually segmenting the tumor burden (providing tumor volume [TV], peak/mean/maximum standardized uptake values [SUV] and tumor chemokine receptor binding on the cell surface [TRB], defined as SUV<sub>mean</sub> multiplied by tumor volume). Clinical parameters included sex, previous therapies, age, Weiss-Score, and Ki67 index. Following imaging, overall survival (OS) was recorded.</p><p><strong>Results: </strong>After [<sup>68</sup>Ga]Ga-PentixaFor PET/CT, median OS was 9 months (range, 1-96 months). On univariable analysis, only higher TRB (per 10 ml, HR 1.004, 95%CI: 1.0001-1.007, P = 0.005) and presence of CXCR4-positive peritoneal metastases (PM) were associated with shorter OS (HR 2.03, 95%CI: 1.03-4.02, P = 0.04). Presence of CXCR4-positive liver metastases (LM) trended towards significance (HR 1.85, 0.9-4.1, P = 0.11), while all other parameters failed to predict survival. On multivariable analysis, only TRB was an independent predictor for OS (HR 1.0, 95%CI: 1.00-1.001, P = 0.02). On Kaplan-Meier analysis, TRB above median (13.3 months vs. below median, 6.4 months) and presence of CXCR4-positive PM (6.4 months, vs. no PM, 11.4 months) were associated with shorter survival (P < 0.05, respectively). Presence of LM, however, was also linked to less favorable outcome (8.5 months vs. no LM, 18.1 months), without reaching significance (P = 0.07).</p><p><strong>Conclusions: </strong>In advanced ACC, elevated tumor chemokine receptor binding on the tumor cell surface detected through [<sup>68</sup>Ga]Ga-PentixaFor PET/CT is an independent predictor for OS, while other imaging and clinical parameters failed to provide relevant prognostic information.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"3643-3650"},"PeriodicalIF":7.6000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11445370/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Nuclear Medicine and Molecular Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00259-024-06800-z","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Background: In patients affected with adrenocortical carcinoma (ACC), C-X-C motif chemokine receptor 4 (CXCR4) is highly expressed in sites of disease in an ex-vivo setting. We aimed to determine the predictive value of CXCR4-targeting [68Ga]Ga-PentixaFor PET/CT for outcome when compared to clinical parameters.

Methods: We identified 41 metastasized ACC patients imaged with [68Ga]Ga-PentixaFor PET/CT. Scans were assessed visually and on a quantitative level by manually segmenting the tumor burden (providing tumor volume [TV], peak/mean/maximum standardized uptake values [SUV] and tumor chemokine receptor binding on the cell surface [TRB], defined as SUVmean multiplied by tumor volume). Clinical parameters included sex, previous therapies, age, Weiss-Score, and Ki67 index. Following imaging, overall survival (OS) was recorded.

Results: After [68Ga]Ga-PentixaFor PET/CT, median OS was 9 months (range, 1-96 months). On univariable analysis, only higher TRB (per 10 ml, HR 1.004, 95%CI: 1.0001-1.007, P = 0.005) and presence of CXCR4-positive peritoneal metastases (PM) were associated with shorter OS (HR 2.03, 95%CI: 1.03-4.02, P = 0.04). Presence of CXCR4-positive liver metastases (LM) trended towards significance (HR 1.85, 0.9-4.1, P = 0.11), while all other parameters failed to predict survival. On multivariable analysis, only TRB was an independent predictor for OS (HR 1.0, 95%CI: 1.00-1.001, P = 0.02). On Kaplan-Meier analysis, TRB above median (13.3 months vs. below median, 6.4 months) and presence of CXCR4-positive PM (6.4 months, vs. no PM, 11.4 months) were associated with shorter survival (P < 0.05, respectively). Presence of LM, however, was also linked to less favorable outcome (8.5 months vs. no LM, 18.1 months), without reaching significance (P = 0.07).

Conclusions: In advanced ACC, elevated tumor chemokine receptor binding on the tumor cell surface detected through [68Ga]Ga-PentixaFor PET/CT is an independent predictor for OS, while other imaging and clinical parameters failed to provide relevant prognostic information.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
C-X-C motif趋化因子受体4导向分子成像对晚期肾上腺皮质癌患者的预测价值。
背景:在肾上腺皮质癌(ACC)患者中,C-X-C motif趋化因子受体4(CXCR4)在体外病变部位高度表达。我们旨在确定 CXCR4 靶向 [68Ga]Ga-PentixaFor PET/CT 与临床参数相比对预后的预测价值:方法:我们确定了41例使用[68Ga]Ga-PentixaFor PET/CT成像的转移性ACC患者。通过手动分割肿瘤负荷(提供肿瘤体积[TV]、峰值/平均值/最大标准化摄取值[SUV]和细胞表面肿瘤趋化因子受体结合[TRB],定义为 SUVmean 乘以肿瘤体积),对扫描进行视觉和定量评估。临床参数包括性别、既往治疗情况、年龄、韦氏评分和Ki67指数。成像后记录总生存期(OS):结果:[68Ga]Ga-PentixaFor PET/CT 显像后,中位生存期为 9 个月(1-96 个月)。单变量分析显示,只有较高的TRB(每10毫升,HR 1.004,95%CI:1.0001-1.007,P = 0.005)和CXCR4阳性腹膜转移灶(PM)与较短的OS相关(HR 2.03,95%CI:1.03-4.02,P = 0.04)。CXCR4阳性肝转移灶(LM)与生存率呈显著相关性(HR 1.85,0.9-4.1,P = 0.11),而所有其他参数均不能预测生存率。在多变量分析中,只有TRB是预测OS的独立指标(HR 1.0,95%CI:1.00-1.001,P = 0.02)。在卡普兰-梅耶尔分析中,TRB高于中位数(13.3个月,而低于中位数,6.4个月)和出现CXCR4阳性PM(6.4个月,而无PM,11.4个月)与较短的生存期有关(P 结论:TRB和CXCR4阳性PM与较短的生存期有关:在晚期 ACC 中,通过[68Ga]Ga-PentixaFor PET/CT 检测到的肿瘤细胞表面肿瘤趋化因子受体结合率升高是预测 OS 的独立指标,而其他成像和临床参数未能提供相关的预后信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
15.60
自引率
9.90%
发文量
392
审稿时长
3 months
期刊介绍: The European Journal of Nuclear Medicine and Molecular Imaging serves as a platform for the exchange of clinical and scientific information within nuclear medicine and related professions. It welcomes international submissions from professionals involved in the functional, metabolic, and molecular investigation of diseases. The journal's coverage spans physics, dosimetry, radiation biology, radiochemistry, and pharmacy, providing high-quality peer review by experts in the field. Known for highly cited and downloaded articles, it ensures global visibility for research work and is part of the EJNMMI journal family.
期刊最新文献
PET-imaging derived prognostic factors for prostate cancer patients with visceral metastases receiving [177Lu]Lu-PSMA radiopharmaceutical therapy (RPT) Simultaneous multiple post-labelling delay ASL MRI and [18F]FDG PET in a mixed memory clinic population and healthy controls. Kalevi Kairemo. Prostate cancer from a nuclear oncology perspective. A personal journey. Springer Nature Switzerland AG 2025, ISBN: 978-3-031-90336-6 Jennifer Schroeder, Joanna R. Fair (editors). Diagnostic imaging: nuclear medicine 4th edition. Elsevier, 2026. ISBN: 978-0-443-28740-4 Recent advances in multimodal imaging of infections: research highlights using Nuclear-Optical imaging
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1